Adequate plasma levels of dolutegravir in combination with ritonavir-boosted darunavir: a pharmacokinetic subgroup analysis of the DUALIS study

J Antimicrob Chemother. 2020 Oct 1;75(10):3082-3084. doi: 10.1093/jac/dkaa234.

Authors

Simon Weidlich¹, Christoph Boesecke², Jochen Schneider¹, Hartwig H F Klinker³, Alexander Zink⁴, Annamaria Balogh⁵, Eva Wolf⁵, Helen Bidner⁶, Christoph D Spinner¹; DUALIS study team

Affiliations

¹ Technical University of Munich, School of Medicine, University Hospital rechts der Isar, Department of Medicine II, Ismaninger Str. 22, 81675 Munich, Germany.
² Bonn University Hospital, Department of Medicine I, Venusberg-Campus 1, 53127 Bonn, Germany.
³ University of Wuerzburg Medical Center, Department of Medicine II, Division of Infectious Diseases, Oberduerracherstr. 6, 97080 Wuerzburg, Germany.
⁴ Technical University of Munich, School of Medicine, University Hospital rechts der Isar, Department of Dermatology and Allergy, Biedersteiner Str. 29, 80802 Munich, Germany.
⁵ MUC Research, Clinical Research Organisation, Karlsplatz 8, 80335 Munich, Germany.
⁶ Technical University of Munich, School of Medicine, University Hospital rechts der Isar, Munich Study Center, Clinical Research Organization, Grillparzerstr. 30, 81675 Munich, Germany.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Anti-HIV Agents* / therapeutic use
Darunavir / therapeutic use
Drug Therapy, Combination
HIV Infections* / drug therapy
HIV Protease Inhibitors* / therapeutic use
Heterocyclic Compounds, 3-Ring / therapeutic use
Humans
Oxazines
Piperazines
Pyridones
Ritonavir / therapeutic use

Substances

Anti-HIV Agents
HIV Protease Inhibitors
Heterocyclic Compounds, 3-Ring
Oxazines
Piperazines
Pyridones
dolutegravir
Ritonavir
Darunavir